Payment overview · 2025
General Payments
$201.69
11 reported records · 7 companies
Healthcare provider profile · identity verified
Troy Allen Davison
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · KINGMAN, AZ · NPI 1114023595
Verified facts
What the public records show
CMS Open Payments records show Troy Allen Davison received $201.69 in general payments during 2025 across 11 reported records.
Amgen Inc. accounted for 31.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.59 | 31.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.21 | 23.4% | 3 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $20.50 | 10.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.35 | 10.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $18.66 | 9.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.02 | 8.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.36 | 7.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $201.69 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.21 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $43.89 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 124 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
124 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 465 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 392 | 92 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 350 | 51 |
| Lisinopril | Lisinopril | 329 | 94 |
| Metformin Hcl | Metformin Hcl | 260 | 68 |
| Losartan Potassium | Losartan Potassium | 256 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 235 | 72 |
| Gabapentin | Gabapentin | 229 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 221 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 175 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 44 |
| Furosemide | Furosemide | 133 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 133 | 16 |
| Trazodone Hcl | Trazodone Hcl | 131 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 124 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 25 |
| Famotidine | Famotidine | 112 | 32 |
| Tramadol Hcl | Tramadol Hcl | 109 | 22 |
| Omeprazole | Omeprazole | 102 | 29 |
| Jardiance | Empagliflozin | 100 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 29 |
| Sertraline Hcl | Sertraline Hcl | 88 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 25 |
| Eliquis | Apixaban | 77 | 13 |
| Warfarin Sodium | Warfarin Sodium | 70 | suppressed |
| Allopurinol | Allopurinol | 69 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 68 | 20 |
| Methocarbamol | Methocarbamol | 67 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 66 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 16 |
| Simvastatin | Simvastatin | 63 | 18 |
| Montelukast Sodium | Montelukast Sodium | 62 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 20 |
| Glimepiride | Glimepiride | 59 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 12 |
| Alprazolam | Alprazolam | 54 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Finasteride | Finasteride | 51 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | suppressed |
| Potassium Chloride | Potassium Chloride | 47 | 14 |
| Lovastatin | Lovastatin | 46 | 12 |
| Atrovent Hfa | Ipratropium Bromide | 45 | suppressed |
| Carvedilol | Carvedilol | 45 | 12 |
| Januvia | Sitagliptin Phosphate | 44 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 44 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 11 |
| Ibuprofen | Ibuprofen | 38 | suppressed |
| Azithromycin | Azithromycin | 37 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Prednisone | Prednisone | 35 | suppressed |
| Clonazepam | Clonazepam | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Meloxicam | Meloxicam | 33 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 13 |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 11 |
| Breyna | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 17 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $201.69 · 11 records | Amgen Inc. | ABRYSVO, AFREZZA, AIRSUPRA, COMIRNATY, Dexcom G6 Transmitter, KRYSTEXXA, OTEZLA, PREVNAR 20, REPATHA, TRELEGY ELLIPTA, TZIELD | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error